Page 68 - Read Online
P. 68

Page 14 of 21                 Dokko et al. Vessel Plus 2022;6:37  https://dx.doi.org/10.20517/2574-1209.2021.121

                                                       [137]
               surgeons more likely to perform the procedure . The risk and benefit of concomitant surgical ablation are
               patient and surgeon dependent and more time is needed to evaluate the long-term outcomes of
               concomitant surgical ablation before it can be expanded for prophylactic use in patients who are in sinus
               rhythm but at risk for POAF. However, prophylactic ablation is promising, especially due to the high
               likelihood of developing POAF after MV surgery and may likely become standard therapy for these
               patients. For prophylactic ablation to be considered, it will be critical to identify risk factors in patients that
               predict specifically persistent POAF and compare its efficacy to prophylactic medical therapy in
               combination and alone [127,128] . Other important prophylactic therapy to consider are routine concomitant
               LAA closure for all patients undergoing MV surgery and transcatheter ablation prior to MV surgery for
               patients with pre-operative atrial fibrillation as a less invasive alternative procedure to concomitant surgical
               ablation.

               Thrombi from atrial fibrillation are most commonly found in the LAA, and its surgical closure may reduce
                                                                               [138]
               the risk of stroke and the need for life-long anticoagulation. Ando et al.  conducted a meta-analysis
               evaluating the impact of LAA closure in patients undergoing cardiac surgery and observed lower 30-day or
               in-hospital mortality and incidence of cerebrovascular accidents in patients who underwent LAA closure,
               especially in patients with pre-operative atrial fibrillation. A weaker association was seen in patients without
                                                                [138]
               pre-operative atrial fibrillation undergoing valve surgery . Due to the high risk of POAF and associated
               increased risk of stroke in patients undergoing MV surgery, prophylactic LAA for all patients undergoing
               MV surgery may be a promising beneficial therapy.


               Transcatheter ablation may also serve as a less invasive and intensive alternative procedure to concomitant
               surgical ablation in patients with pre-operative atrial fibrillation undergoing MV surgery. Concomitant
               surgical ablation lengthens the MV surgery, may require longer bypass time and is associated with
               permanent pacemaker implantation . Previous studies with transcatheter ablation have shown successful
                                              [75]
               long-term cardioversion albeit requiring repeat ablations [96-98] . Due to its shorter procedural time and less
               invasive nature, transcatheter ablation may serve as a safer prophylactic ablative therapy and in combination
               with catheter ablation of the cavotricuspid isthmus has been shown in a meta-analysis to reduce the
               incidence of atrial fibrillation in patients with atrial flutter .
                                                                [139]

               CONCLUSION
               Both pre- and post-operative atrial fibrillation are common in the MV disease population, yet the reasons
               behind the development, optimal treatment, and longer-term impact of these arrhythmic conditions are not
               yet completely understood. Pre-operative atrial fibrillation is likely attributable to left atrial enlargement
               associated with MV stenosis and regurgitation. If it is by itself a significant risk factor or if it is a surrogate
               for impaired myocardium is yet to be determined. Regardless, the management of these high-risk patients
               warrants careful consideration. Therapeutic strategies to address pre-operative atrial fibrillation include
               medical management and ablation. The etiology of POAF is most likely multifactorial and has been linked
               to other pre-operative risks, intra-operative processes of care, as well as surgeon-based experience. Although
               there is no consensus regarding the impact of POAF on long-term outcomes, POAF appears to negatively
               impact mortality, and thus with more studies would warrant prophylactic therapy through left atrial
               appendage closure, transcatheter ablation, or concomitant surgical ablation.

               DECLARATIONS
               Authors’ contributions
               Substantive intellectual contribution, conception, and design: Dokko J, Novotny S, Santore LA, Shroyer
               ALW, Bilfinger T
   63   64   65   66   67   68   69   70   71   72   73